Polymer-lipid Nanocomplex for Enhanced Hydrophobic Drug Solubility
Summary
The European Patent Office published patent application EP3941439A1 for the Council for Scientific and Industrial Research covering a polymer-lipid nanocomplex formulation that enhances aqueous solubilisation and absorption of hydrophobic active compounds. The invention addresses drug delivery challenges for poorly soluble pharmaceuticals across multiple therapeutic areas including anti-obesity, anxiolytic, antidepressant, anti-inflammatory, antimicrobial, and antiparasitic applications.
What changed
EPO published patent application EP3941439A1 on March 25, 2026, granting the Council for Scientific and Industrial Research protection for a polymer-lipid nanocomplex technology that improves solubility and absorption of hydrophobic drugs. The designated states cover major European markets including DE, FR, GB, IT, ES, NL, BE, CH, and others. The patent claims formulations using specific lipid components and polymer matrices for drug delivery applications.
Patent publication does not create compliance obligations. Entities developing competing formulations for hydrophobic drug delivery should conduct freedom-to-operate analysis. The 20-year patent term from priority date will provide market exclusivity. No action required unless the entity's R&D involves similar polymer-lipid nanocomplex technologies.
Source document (simplified)
POLYMER-LIPID NANOCOMPLEX FOR ENHANCED AQUEOUS SOLUBILISATION AND ABSORPTION OF HYDROPHOBIC ACTIVE COMPOUNDS
Publication EP3941439A1 Kind: A1 Mar 25, 2026
Applicants
Council for Scientific and Industrial Research
Inventors
NKUNA, Tshepo Patric, KALOMBO, Michel Lonji
IPC Classifications
A61K 9/107 20060101AFI20201120BHEP A61K 9/51 20060101ALI20201120BHEP A61K 9/19 20060101ALI20201120BHEP A61K 47/02 20060101ALI20201120BHEP A61K 47/08 20060101ALI20201120BHEP A61K 47/10 20170101ALI20201120BHEP A61K 47/12 20060101ALI20201120BHEP A61K 47/26 20060101ALI20201120BHEP A61K 47/32 20060101ALI20201120BHEP A61K 47/34 20170101ALI20201120BHEP A61K 31/05 20060101ALI20201120BHEP A61K 31/137 20060101ALI20201120BHEP A61K 31/496 20060101ALI20201120BHEP A61P 3/04 20060101ALI20201120BHEP A61P 25/22 20060101ALI20201120BHEP A61P 25/24 20060101ALI20201120BHEP A61P 29/00 20060101ALI20201120BHEP A61P 31/06 20060101ALI20201120BHEP A61P 31/10 20060101ALI20201120BHEP A61P 31/12 20060101ALI20201120BHEP A61P 33/06 20060101ALI20201120BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.